Insider · CIK 0001797826
Nancy Thornberry
Files at VRTX (VERTEX PHARMACEUTICALS INC / MA), SDGR (Schrodinger, Inc.), DNLI (Denali Therapeutics Inc.). First filing Sep 4, 2026, latest Sep 4, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DNLI: Denali Therapeutics Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Denali Therapeutics Inc. | $262k 11,439 shares | -37% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | DNLI Denali Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -10,824 | $22.85 | $247k | 20,301 | 38 d ago |
| Sep 2, 2026 | DNLI Denali Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -615 | $23.74 | $15k | 19,686 | 38 d ago |
| Jun 18, 2025 | SDGR Schrodinger, Inc. | AGrant or award Common Stock | +5,997 | $0.00 | $0 | 17,247 | Jun 20, 2025 |
| Jun 18, 2025 | SDGR Schrodinger, Inc. | AGrant or award Stock Option (right to buy)derivative | +9,341 | $0.00 | $0 | 9,341 | Jun 20, 2025 |
| Jun 3, 2025 | DNLI Denali Therapeutics Inc. | AGrant or award Common Stock | +6,037 | $0.00 | $0 | 24,717 | Jun 5, 2025 |
| Jun 3, 2025 | DNLI Denali Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +18,111 | $0.00 | $0 | 18,111 | Jun 5, 2025 |
| May 1, 2025 | VRTX VERTEX PHARMACEUTICALS INC / MA | AGrant or award Common Stock | +398 | $0.00 | $0 | 2,035 | May 5, 2025 |
| May 1, 2025 | VRTX VERTEX PHARMACEUTICALS INC / MA | AGrant or award Stock Option (Right to Buy)derivative | +1,199 | $0.00 | $0 | 1,199 | May 5, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.